VCEL Vericel Corporation
$38.34▲ +1.24%
Healthcare
Other
After hours
$38.34▲ +0.00%
Sep 11, 7:30 PM ET
Volume 503.5K
Avg Volume (10D) 443.9K
Key Metrics & Fundamentals
Market Cap
$1.96B
P/E Ratio
79.9
Div Yield
–%
52W Range
28.95 - 49.32
% vs 50 MA
-13.19%
% vs 200 MA
0.50%
RSI-14
31.2
MACD Histogram
-0.3100
Beta (1Y vs SPY)
0.88
Free Cash Flow
$14.26M
Gross Rev
$77.46M
Gross Profit
$56.40M
EBITDA
$5.99M
COGS
$21.06M
Operating Exp
$55.97M
Operating Income
$434,000
EBIT
$434,000
Pretax Income
$2.21M
Net Income
$2.21M
EPS (Diluted)
0.04
Price & Volume History
Loading chart…
Recent News
Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026
GlobeNewswire · Sep 8, 2026 12:30 PM
MediWound Q2 Earnings Call Highlights
MarketBeat · Aug 13, 2026 6:04 PM
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · Aug 13, 2026 11:00 AM
Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison
IPO-Edge.com · Aug 3, 2026 2:55 PM
Truist Raises Price Target on Vericel to $58 From $54, Keeps Buy Rating
MT Newswires · Jul 31, 2026 12:05 PM
Vericel Q2 Earnings Call Highlights
MarketBeat · Jul 30, 2026 9:03 PM
Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates
Zacks · Jul 30, 2026 1:35 PM
Vericel Swings to Q2 Net Income, Revenue Rises; Full-Year 2026 Revenue Guidance Raised
MT Newswires · Jul 30, 2026 1:29 PM
Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program
GlobeNewswire · Jul 30, 2026 11:55 AM
Truist Securities Adjusts Price Target on Vericel to $54 From $42, Maintains Buy Rating
MT Newswires · Jul 16, 2026 12:57 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See VCEL's money flow as a full page
Social Sentiment
Avg +0.60 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.